KemPharm to Present at Biotech Showcase 2017
04 January 2017 - 11:33PM
KemPharm, Inc. (Nasdaq:KMPH), a clinical-stage specialty
pharmaceutical company focused on the discovery and development of
proprietary prodrugs, announced today that its President and Chief
Executive Officer, Travis Mickle, Ph.D., will present at Biotech
Showcase 2017 to be held January 9-11, 2017, at the Hilton San
Francisco Union Square.
Details of KemPharm's presentation are as follows:
Event: |
|
Biotech
Showcase 2017 |
Date: |
|
Tuesday, January 10,
2017 |
Time: |
|
3:00 p.m. (Pacific
Time) |
Location: |
|
Hilton San Francisco
Union Square |
The presentation will be webcast and available on the Investor
Relations section of the KemPharm website at
http://investors.kempharm.com/.
About KemPharm
KemPharm is a clinical-stage specialty
pharmaceutical company focused on the discovery and development of
proprietary prodrugs to treat serious medical conditions through
its Ligand Activated Therapy (LAT) platform technology.
KemPharm utilizes its LAT platform technology to generate improved
prodrug versions of FDA-approved drugs in the high need areas of
pain, ADHD and other central nervous system (CNS) disorders.
KemPharm’s co-lead clinical development candidates are KP415, an
extended-release (ER) prodrug of methylphenidate for the treatment
of attention deficit hyperactivity disorder (ADHD), and KP201/IR,
an acetaminophen (APAP)-free formulation of the company’s immediate
release (IR) abuse deterrent hydrocodone product, KP201. For
more information on KemPharm and its pipeline of prodrug product
candidates visit www.kempharm.com.
Investor Contacts:
Jason Rando / Joshua Drumm, Ph.D.
Tiberend Strategic Advisors, Inc.
212-375-2665 / 2664
jrando@tiberend.com
jdrumm@tiberend.com
Media Contact:
Daniel L. Cohen
Executive VP, Government and Public Relations
KemPharm, Inc.
202-329-1825
dcohen@kempharm.com
KemPharm (NASDAQ:KMPH)
Historical Stock Chart
From Apr 2024 to May 2024
KemPharm (NASDAQ:KMPH)
Historical Stock Chart
From May 2023 to May 2024